Human malignant melanoma represents a difficult therapeu tic challenge to both medical scientists and practicing physi cians. However, the biologic uniqueness of the tumor may provide opportunities for exploitation in therapeutics. This study proposed to undertake a systemic approach to the chemotherapy of malignant melanoma based upon the uniqueness of pigment-cell metabolic pathway pertaining to conversion of tyrosine and dopa with subsequent formation of melanin by tyrosinase and its related enzymes. The sulphur homologue of tyrosine, cysteinylphenol (CP), its amine de rivative, cysteaminylphenol (CAP), and their N-acetyl and a-methyl derivatives have been synthesized and tested in in vivo and in vitro melanocytotoxicity and antimelanoma ef fects. These phenolic thioethers (PTEs) and phenolic thioether amine (amides) (PTEAs), which are substrates of H uman malignant melanoma represents a difficult therapeutic challenge to the scientist and physician. Whereas great progress has been made in the early diagnosis of stage I melanoma (no palpable nodes) and survival has dramatically increased in the past decade or two, the mortality continues to increase at 3% per year [1] . Furthermore, we have no therapy for high-risk primary melanoma at stage I (lesions deeper than the level IV or 3.5 mm in tumor thickness) and no therapy at all for stage III melanoma. Cancer chemotherapy has failed, immunotherapy is virtually ineffective, and the overwhelming majority of melanomas are not radiorespon sive [2] .
Human malignant melanoma represents a difficult therapeu tic challenge to both medical scientists and practicing physi cians. However, the biologic uniqueness of the tumor may provide opportunities for exploitation in therapeutics. This study proposed to undertake a systemic approach to the chemotherapy of malignant melanoma based upon the uniqueness of pigment-cell metabolic pathway pertaining to conversion of tyrosine and dopa with subsequent formation of melanin by tyrosinase and its related enzymes. The sulphur homologue of tyrosine, cysteinylphenol (CP), its amine de rivative, cysteaminylphenol (CAP), and their N-acetyl and a-methyl derivatives have been synthesized and tested in in vivo and in vitro melanocytotoxicity and antimelanoma ef fects. These phenolic thioethers (PTEs) and phenolic thioether amine (amides) (PTEAs), which are substrates of H uman malignant melanoma represents a difficult therapeutic challenge to the scientist and physician. Whereas great progress has been made in the early diagnosis of stage I melanoma (no palpable nodes) and survival has dramatically increased in the past decade or two, the mortality continues to increase at 3% per year [1] . Furthermore, we have no therapy for high-risk primary melanoma at stage I (lesions deeper than the level IV or 3.5 mm in tumor thickness) and no therapy at all for stage III melanoma. Cancer chemotherapy has failed, immunotherapy is virtually ineffective, and the overwhelming majority of melanomas are not radiorespon sive [2] .
In reviewing the major advances in the chemotherapy of cancer, it is immediately apparent that the most remarkable successes have occurred when the biologic uniqueness of a given tumor was ex ploited. The biologic uniqueness of the melanoma cell resides in this tendency to retain the biochemical apparatus for the conversion of tyrosine to melanin in the highly specialized organelle, the me lanosome [3] . This differentiated morphologic and biochemical property is unique to the melanocyte and its malignant counterpart, and the activity of this pathway is enhanced in most melanoma cells. It can also be highly exaggerated, even in amelanotic melanoma, by melanocyte stimulating hormone (MSH) (Fig 1) . Our previous study, using White Leghorn chicken as an animal model of human melanoleucoderma, indicated that melanin/melanosome p er se, if overproduced, is toxic to melanocytes and may even kill them, thus providing a rationale for utilizing melanin precursors and metabo lites for selective degradation of melanoma cells [4] . This report describes, first, the background of the utilization of melanin precursors as potential chemotherapeutic agents for mela noma by introducing several natural melanin precursors/metabo lites, i.e., tyrosine, dopa, dopaquinone, dihydroxyindole, and cys teinyldopa, as well as phenol and catechol, which are well-known depigmenting agents. We will then summarize our recent ap proaches to experimental melanoma chemotherapy, which are based on the exploitation of metabolic pathways of melanin syn thesis.
METABOLISM OF MELANIN PRECURSORS AND TH EIR SELECTIVE MELANOCYTOTOXICITY
The metabolites of melanin pigmentation that may be useful for development of cytotoxic agents can be grouped into two major categories: a) enzymic oxidation of tyrosine (monohydroxy)/dopa (dihydroxy) and b) auto-oxidation of 5,6-dihydroxyindole (eume- Cya�eiD..
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s---y CO ely Figure 1 . Metabolic pathway of melanin synthesis from conversion of tyrosine to dopa and then to dopaquinone in the presence of tyrosinase. Eumelanin, brown-black pigment, is synthesized through the oxidation of dihydroxyindole (DHI) with an intimate interaction of dopachrome tautomer ase and metal ions. Pheomelanin, yellow-red pigment, is formed through the incorporation of cystein or other related sulphydryl compound, glutathione (GSH). Structurally, eumelanin is composed mainly of heteropolymer units of 5,6-DHI and 5,6-dihydroxyindole-2-carboxylic acid whereas pheome lanin is made of benzothiazine units. Copolymerization of dopa and cysteinyldopa may take place, leading to the production of mixed-type melanin. Trichochrome is a derivative of a conjugated benzothiazine dimer. The drawing is modified from the original figure prepared by Professor Prota. lanin)/ 5-S-cysteinyldopa (pheomelanin) [5] . In the past, a number of approaches have been used to examine derivatives representing each of these metabolites as potential models for the design of com pounds that will exhibit useful clinical cytotoxicity for melanoma cells.
Tyrosine Tyrosine serves as the starting material for the biosyn thesis of melanin. The degree and type of melanin pigmentation of melanoma cells can be influenced by changing the concentration of tyrosine or cysteine and related sulfhydryl compound in the growth medium [6] . Therefore, through an increased melanotic pigmenta tion by raising the concentration of tyrosine, one can induce signifi cant toxicity to melanin-g roducing cells as compared to their non pigmented counterparts [7] . A major difficulty in the application of this approach for melanoma chemotherapy is the fact that tyrosine is an amino acid used extensively in general cellular protein synthesis. In addition, rapidly growing pigmented cells incorporate only about 5% of the tyrosine used in general cellular protein synthe sis [8] .
Dopa/Dopamine Although dopa is an amino acid, it is not nor mally found in cellular proteins. Exogenous dopa, unlike tyrosine, has been shown to be selectively incorporated into melanoma cells [9] . Dopa and related catecholic compounds have been shown to possess antimelanoma effects in many in vitro and some in vivo sys tems [10] . Dopamine, a major metabolite of dopa, has also been shown to be a highly potent inhibitor of murine melanoma cell proliferation, both in vivo and in vitro. Dopamine has been infused into advanced-staged melanoma patients with some reduction in the labeling index of tumor cells [11] . The major limitations of dopa derivatives appear to be a) instability, b) insufficient lethality of dopa toward neoplastic cells in vivo, and c) low physiologically tolerable dosages of 6-hydroxydopa and other catechols due to general cyto toxicity. A new class of compounds, the dopa phosphates, has been reported recently. These compounds, in which either the 3-or 4-position of hydroxyl groups of dopa are monoesterified with phosphate, are stable [12] and, at high concentrations, appear to be cytotoxic toward murine melanoma cells in vitro. However, no data are available as yet regarding their in vivo antimelanoma effect.
Dihydroxyindole/Cysteinyldopa Dihydroxyindole is a pre cursor of eumelanin produced from dopaquinone by non-enzymic reaction. It has been shown to be cytotoxic to melanoma cells in vitro [13] . This compound is an extremely reactive neutrophile and elec trophile, which limits its use as an antitumor agent. 5-S-cysteinyl dopa is also a precursor of pheomelanin, and has also been shown to possess an in vitro anti-melanoma effect, which was better than that of dopa and was also active against L1210 leukemia [14] . Again, no in vivo data were provided.
Catechols As early as 1974, we studied by electron microscopy the subcellular processes occurring during/after topical application of hydro quinone to black skin, and clarified the possible mechanism of melanocytotoxicity by catecholic compounds [15] . These com pounds release quinone derivatives, which selectively affect the mel anogenesis and eventually cause melanocyte death. In addition, by examining the in vitro incorporation of leucine in a cell-free protein inhibition system, one type of catechol, 4-isopropylcatechol, dra matically inhibited this process in melanoma cells that contained a high level of tyrosinase. The enhanced inhibition was 'also found, however, in the cell-free liver system when tyrosinase was added (from 0 to 80% inhibition). Aerobic oxidative products of catechol were not responsible for this inhibition, indicating that the tyrosin ase-dependent cytotoxicity was probably mediated by some inter mediate that occurs in an early stage of enzymic oxidation [16] .
Phenols In the studies of Vogel and colleagues [17, 18] , a stable phenol [gamma-L-glutaminyl-4-hydroxybenzene (GHB)] was shown to prolong survival of C57BL mice inoculated with mela noma cells and to inhibit the growth of melanoma cells in vivo. However, GHB was shown to be a poor substrate of mammalian tyrosinase, and hydrolyzed in animals by gamma glutaminyl trans peptidase to release p-aminophenol as a product, which is responsi-ble for melanocytotoxicity [19] . Thus, GHB itself is not appropriate for a rational chemotherapy.
Recently three new catecholic analogues of GHB have been syn thesized as potential antimelanoma drugs. Compounds 1 and 2 (NSC 337779 and 337780) were found to be oxidized by tyrosinase to quinones. Cytotoxic activity was blocked by a tyrosinase inhibi tor. These two compounds exhibited greater potency and selectivity against melanoma than did the natural product, L dopa-methyl ether [20] . Again the in vivo antimelanoma effects of these com pounds need to be clarified. Riley and his associates [21] indicated that 4-hydroxyanisole is a potent depigmenting agent and has some in vivo and in vitro antimelanoma effect in animals and humans. A number of rl:cent studies, however, indicated that 4-hydroxyanisole does not have any selective cytotoxicity to pigment cells [22] .
DEVELOPMENT OF TYROSINE HOMOLOGUE, CYSTEINYLPHENOL (CP), AND ITS AMINE DERIVATIVE, CYSTEAMINYLPHENOL (CAP), AND THEIR BIOLOGIC AND PHARMACOLOGIC EFFECTS
Synthesis ofCP and CAP, and Their Enzymic Kinetics With Tyrosinase We have recently synthesized a sulphur homologue of tyrosine, cysteinylphenol (CP) and its amine derivative cystea minylphenol (CAP), and related compounds [23] (Fig 2) . Phenols and catechols are combined with sulphur using either cysteine or cysteamine to synthesize these phenolic thioethers (PTEs) or their amines, phenolic thioether amines (PTEAs), respectively (Table I) . Sulphur was added, a) because it may increase the u p take of the compound into the cells by virtue of lipophilicity, and b) because the conjugation of sulphur may make the compound a better substrate for tyrosinase. These synthetic compounds include 4-S-cysteinyl phenol (CP), 2-S-CP, 4-S-cysteaminylphenol (CAP), 4-S-cystein ylcatechol (Ce), 2-S-CC, 2-cysteinylhydroquinone (CHQ), 2-S cysteinylresorcinol (CR) , and 2-S-cysteinyldopa (CD). Only 4-S-CP, 4-S-CAP, and 4-S-CC were found to be tyrosinase sub strates but 2-S-isomers were not (Table I ).
1 .. Vivo Melanocytoxicity of CP and CAP in Black/White Mice In our initial screening, we tested the in vivo depigmenting potency of seven compounds, i.e., 4-S-(2-S)-CP, 4-S-(2-S)-CAP, 4-S-CC, 2-S-CHQ, and 2-S-CR using C57 black mice. After a single intraperitoneal injection of compounds (200 -400 mg/kg of body weight), 4-S-CP and 4-S-CAP showed the depigmentation of newly growing black hair. Depigmentation was most prominent in black mice treated with 4-S-CAP (close to 80%) and then with 4-S-CP. Catecholic compounds were easily oxidized by air and not practical for in vivo study (Table I) . None of the depigmentation was observed by 2-S-CP and 2-S-CAP, which were not tyrosinase sub strates (Table I) . Under electron microscopy, degenerating changes were seen as early as 2 h after an intraperitoneal administration, showing vacuolation of the entire cytoplasm and later, at 48 h, the lysis of the whole cell. In contrast, the non-melanin-forming cells, e.g., keratinocytes, fibroblasts, and albino melanocytes, did not show any degenerative changes [24] .
1 .. "i"o and 1 .. Vitro Selective Accumulation of CP and CAP into Melanoma-Bearing Mice and Melanoma Cells To fur ther characterize the selective melanocytotoxicity of melanin pre cursors, 4-S-CP and 4-S-CAP were radio labeled with 3H and 14C, respectively [25, 26] , and their incorporation into melanoma tissues were evaluated in B16 melanoma-bearing mice. Silver grains of 4-S-CP were selectively accumulated in melanoma cells, whereas they were not seen in necrotic tissues [27] . 14C-4-S-CAP showed a biodistribution similar to that of 4-S-CP. It was, however, also incorporated into the eye [28] . selective transport system through membrane recognition of either cell surface or melanosome-parricle surface, there may be a number of possibilities to account for this selective accumulation of CAP in melanoma cells, and all these are related to the intramelanocytic metabolisms, e.g., a) enzymic reactions of tyrosinase-related pro teins such as dopachrome tautomerase or b-Iocus protein (HMSA-5) [29, 30] or b) a specific binding property of PTE A to melanin metab olites in a way similar to that of chloroquine and quinone derivatives [31] .
1 .. Vivo Antimelanoma Effect of CP and CAP, and Increased Survival The in vivo antimelanoma effects of CP, CAP, and re lated compounds were evaluated by a) direct growth inhibition of murine melanoma and b) the increased life-span (ILS) of B16 mela noma-bearing mice (Table I) [23] . 4-S-CAP showed the highest antimelanoma effect on the growth inhibition (45-53%). 4-S-CP also showed some growth inhibition (33%), which was still better than that of DTIC (NSC 45388; 23%), a drug known to be most consistently effective for human melanoma. Importantly, 4-S-CAP possessed a significant antimelanoma effect in ILS (49%). Similar to depigmenting potency, the in vivo antimelanoma effect was seen only with 4-S-CP and 4-S-CAP, tyrosinase substrates, but not with their 2-S-isomers, which were not tyrosinase substrates (Table I) . 4-S-CP and 4-S-CAP require a catalytic amount of dopa for optimal mammal ian tyrosinase activity. The majority of L-dopa, when ad ministered intravenously, was decarboxylated (ap \? roximately 64%) and metabolized into catecholamine pathway [32] . To enhance the potential anti-melanoma effect and to inhibit the decarboxylation of these two synthetic compounds, L-dopa and antidecarboxylase (carbidopa) were given simultaneously. Whereas groups of 4-S-CP plus L-dopa plus carbidopa showed a minimal increase in antime lanoma effect, the group treated with 4-S-CAP plus L-dopa plus carbidopa revealed an increased inhibition in in vivo melanoma growth (64%) as compared to that of 4-S-CAP alone (49%) [33] .
1 .. Vitro Transport Mechanism of CP Into Melanoma Cells How melanin precursors/tyrosinase substrates are transported into pigment cells is still unknown. The transport system of 4-S-CP was studied in comparison to that of tyrosine for this purpose. Firstly, we determined which one, or combination of, amino acid transport systems, e.g., systems L and T (which transport neutral amino acid with branched or aromatic side chains), and systems A and ASC (which transport neutral amino acid with smaller side chains), would be involved in tyrosine transport into melanoma cells. Our result of Km and Vmax for the Na+-independent transport system and competitive inhibition studies indicated that system L is in volved in tyrosine transport. This one transport system supplies all the tyrosine required for both cell growth and melanin synthesis. Secondly, studies of sequential competitive inhibition tests between tyrosine and 4-S-CP were carried out, and 4-S-CP was found to share the same system L transport for the incorporation into mela noma cells [34]. Table I ). The rates of protein synthesis inhibition by natural melanin precursors, e.g., tyrosine, dopa, and 5-S-cysteinyldopa, were practically zero or min imal, being -6.6%, -3.6%, and 6.9% respectively. Secondly, treatment of human melanoma cells with 4-S-CAP for 24 h re sulted in a slight increase in the proportion of cells in G2 plus M phase of the cell cycle. Simultaneous treatment with Colcemid (1 mg/ml) blocked the controls in G2 + M, but had little effect on the DNA synthesis of the 4-S-CAP-treated cultures, indicating that there was no phase-specific arrest of the cell cycle by 4-S-CAP. When the tyrosinase activity and the amount of tyrosinase itself was measured, 4-S-CAP -treated cells showed a marked decrease of the a.
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activity, suggesting the involvement of enzymic reaction of tyro sinase in 4-S-CAP-mediated toxicity [35] . Thirdly, the in vitro reaction of CP and CAP with intracellular thiol-dependent en zyme, e.g., DNA polymerase a, was studied. As the model of a thiol-dependent enzyme, we employed alcohol dehydrogenase (AD H). In the presence of tyrosinase, we found that both 4-S-CP and 4-S-CAP reacted with cysteine residues in ADH, and that 4-S CAP possessed a higher ability for binding with ADH, as much as five times that of 4-S-CP, explaining partly a much higher melano cytotoxicity potency, protein synthesis inhibition, and antimelan oma effect of 4-S-CAP than 4-S-CP (Table I ) [36] .
Development of New Analogues of 4-S-CAP, and their Tyr
osinase and Non-Tyrosinase-Mediated Cytotoxicity One of the difficulties in utilizing 4-S-CAP as an in vivo antimelanoma agents was that it had a limited solubility and a low LDso value. Furthermore, in an attempt to develop antihypertensive agents, Padgette et al [37] prepared 4-S-CAP and found this compound to be a good substrate for plasma monoamine oxidase. Kawase et al [38] previously reported that various 3-substituted propylamines exerted cytotoxicity through corresponding aldehydes produced by enzy matic oxidation and deamination. Indeed, we found that the low LDso of 4-S-CAP may be attributable to this monoamine-oxidase interaction. To overcome this difficulty a new derivative of 4-S CAP, N-Acetyl(Ac)-4-S-CAP, was prepared and tested in vivo cyto toxicity. We found that N-Ac-4-S-CAP possesses a high LDso value. It was a substrate of mamma lian tyrosinase, but not of mono amine oxidase [39] , and its LDso was 1,400 mg/kg of body weight. In addition, five other homologues ofN-Ac-4-S-CAP were synthe sized; a-methyl-4-S(2-S)CAP, 4-S(2-S)-homo-CAP, and N,N'-di methyl-4-S-CAP. Firstly, their in vitro melanocytoxicity was tested [40] . 4-S-CAP and 4-S-homo-CAP exhibited a marked melanocy totoxicity to cultured human melanoma cells with effects much greater (40 times) than those of a-methyl-4-S-CAP and N,N'-di methyl-4-S-CAP. The cytotoxicity of the two former amines was completely prevented by semicarbazine, a monoamine oxidase in hibitor. Alpha-methyl-4-S-CAP was, however, found to exert higher cytotoxicity to cultured cells with higher tyrosinase activity and melanin content. These results suggest that the in vitro cytotox icity of 4-S-CAP and 4-S-homo-CAP is mediated through conver sion to aldehydes, whereas that of a-methyl-4-S-CAP is solely de pendent on tyrosinase activity. We expect that N-Ac-4-S-CAP will take the same tyrosinase-dependent melanocytotoxicity (Table II) .
In Vivo Melanocytotoxicity by N-Ac-4-S-CAP and Related
Compounds We then tested the melanocytotoxicity of these six new compounds by in vivo depigmenting potency using murine black hair follicles. Follicular melanocytes were examined to assess the degree of melanocytotoxicity; N-Ac-4-S-CAP produced the highest degree of melanocytotoxicity (98%), both given intraperitoneally or subcutaneously (Fig 3) . a-methyl-4-S-CAP and 4-S-CAP were almost equally effective in intraperitoneal administration, their melanocytotoxicity potency being 89% and 87%, respectively. A similar melanocytotoxicity potency was observed in dark skin treated topically with N-Ac-4-S-CAP [41] . Interestingly, 4-S homo-CAP showed a minimum degree of melanocytotoxicity po tency intraperitoneally (12%), whereas a much higher melanocyto toxicity was noted subcutaneously (64%) as compared to that of a-methyl-4-S-CAP (58%) and 4-S-CAP (47%) subcutaneously (Table II) [42] .
In Vivo Antimelanoma EfFect by N-Ac-4-S-CAP Extending the above screening, the in vivo antimelanoma effect is tested in mice that are inoculated with murine and human melanoma cells. We firstly tested, after intraperitoneal injections of 4-S-CAP or N-Ac-4-S-CAP, the inhibition of lung colony formation by B16 FlO melanoma cells in C57 black mice. 4-S-CAP and N-Ac-4-S-CAP were almost equally effective, reducing the lung colonies to 32% and 25% of mean control respectively [42] . Secondly, the same in vivo antimelanoma effect was tested in mice with subcutaneously inoculated B 16 melanoma tissues. A dose-dependent antimelanoma effect was observed in N-Ac-4-S-CAP given from 200 mg/kg to 1200 mg/kg, showing 32% and 71 % growth inhibition, respec tively [33] . Thirdly, in vivo antimelanoma effect ofN-Ac-4-S-CAP Figure 3 . Development of white amelanotic hair in C57 black mice after a single intraperitoneal injection of N-Ac-4-S-CAP (400 mg/kg). To syn chronize the hair cycle, black hair was epilated and then N-Ac-4-S-CAP was given at day 5. (Fig 4) . Monoaminergic cells, especially monoaminergic neurons, pos sess/share many biologic and biochemical properties in common with melanocytes. Both cell types are dendritic, derive from the neural crest, produce specific granules (chromaffin granules or mela nosomes), and convert tyrosine to produce pigments (catechol amines or melanin) in the presence of enzyme (tyrosine hydroxylase or tyrosinase). Monoaminergic cells possess two transport systems, ionic form of the amine that binds to the transporter is not known, but some evidence suggests that the amine is transported in its un charged form. The chromaffin granule transporter has low specific ity; it translocates with similar efficiency not only dopamine, norepi nephrine, and epinephrine, but also monoamines that are not present in the adrenal medulla, such as serotonin and tyramine.
Monoaminergic cells also possess a second class of monoamine up take systems located on the plasma membrane. These systems are secondary active transporters but differ from the vesicular system. Our synthetic PTEAs may take uptake processes similar to those of the above amine transport. However, melanoma cells may also have specific binding proteins [43] . The latter possibility of selective accum ulation and incorporation of PTEAs to melanoma cells would be direcdy or indirecdy related to some important intracellular en dogenous metabolic pathway [44, 45, 46] . Our PTEAs selectively disintegrated in vivo the melanocytes that were engaged in active melanin biosynthesis, but not albino melanocytes, in which there was no melanin biosynthesis and active tyrosinase. Melanin biosyn thesis involves several steps of reduction and oxidation initialed by tyrosinase. As can be seen in Figs 4 and 5, we expect that the same reaction would happen to our PTEAs, forming melanin-like pig ments. We therefore suspect that radicals are involved in the PTEA melanocytotoxicity. The cyclizing quinones from PTEAs can give rise to two structural isomers and, accordingly, two different types of secondary radicals (I and II) can be formed as specified in Fig 5. 
MELANIN PRECURSOR AND ANTIMELAN OMA EFFECT 237S
The intracellular level of glutathione may also control the toxic effect of these radicals [47, 48] .
As a possible explanation of the cytotoxicity of substitute phenols, e.g., 4-hydroxyanisole, Riley [21] proposed that tyrosinase-cata lyzed oxidation gives rise to ortho-quinones that exhibit a relatively high degree of reactivity. In studies of catechols, e.g., L-dopa, and gamma -L-glutaminyl-4-hydroxybenzene, Graham et al [49] have postulated that catechols are oxidized by tyrosinase to o-quinone forms that react with sulphydryl reagents, thus inhibiting the activ ity of thiol-dependent cellular enzymes such as DNA polymerase a. Similarly, CP and CAP can be oxidized by tyrosinase to catecholic forms (cysteinylcatechol and cysteaminylcatechol) and then to the corresponding quinone forms that may conjugate with sulphydryl enzyme in cells. We found that both 4-S-CP and 4-S-CAP conju gate with cysteine residues in sulphydryl enzyme. The sulphydryl enzyme can therefore be another source of PTEA-binding protein within melanoma cells.
In conclusion, we have recendy synthesized 23 compounds of sulphur homologue of melanin precursors and related analogues to establish a rational chemotherapeutic agent for melanoma based upon melanin biosynthesis. 4-S-CP and 4-S-CAP are tyrosinase substrates and found to be potent melanocytotoxic and anti-melan oma agents, 4-S-CAP being much better than 4-S-CP. 4-S-CAP, however, has some inherent difficulty in practical use. New com pounds, N-Ac-and a-methyl-4-S-CAP, were developed. Both showed a marked in vivo melanocytotoxicity (78-99%). Impor tandy, N-Ac-4-S-CAP, which was found to be a good tyrosinase substrate, showed 75% of in vivo growth inhibition of melanoma cells grown in mice. Melanin synthesis pathway is highly elevated in malignant melanoma. This pathway, however, does not play any essential role in the host. Therefore, the potential agent need not discriminate between normal and malignant cells, but rather melan ocytic and non-melanocytic cells.
